What do German Molecular Tumor Boards recommend in patients with PIK3CA-mutated tumors?: Launch and first results from the German Transsectoral Molecular Tumor Board exchange platform Deutschland
Introduction: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive p...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2024
|
| In: |
Oncology research and treatment
Year: 2024, Jahrgang: 47, Heft: 9, Pages: 410-419 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000539217 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000539217
|
| Verfasserangaben: | Ina Pretzell, Alexander Desuki, Annalen Bleckmann, Sonja Loges, Anke Reinacher-Schick, C. Benedikt Westphalen, Sebastian Lange, on behalf of TEAM-D Participants |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1912772132 | ||
| 003 | DE-627 | ||
| 005 | 20250716220138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241217s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000539217 |2 doi | |
| 035 | |a (DE-627)1912772132 | ||
| 035 | |a (DE-599)KXP1912772132 | ||
| 035 | |a (OCoLC)1528015538 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pretzell, Ina |e VerfasserIn |0 (DE-588)1351349058 |0 (DE-627)1912772531 |4 aut | |
| 245 | 1 | 0 | |a What do German Molecular Tumor Boards recommend in patients with PIK3CA-mutated tumors? |b Launch and first results from the German Transsectoral Molecular Tumor Board exchange platform Deutschland |c Ina Pretzell, Alexander Desuki, Annalen Bleckmann, Sonja Loges, Anke Reinacher-Schick, C. Benedikt Westphalen, Sebastian Lange, on behalf of TEAM-D Participants |
| 264 | 1 | |c September 2024 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 7. May 2024 | ||
| 500 | |a Gesehen am 17.12.2024 | ||
| 520 | |a Introduction: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field. Methods: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented. Results: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting. Conclusion: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals. | ||
| 700 | 1 | |a Desuki, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bleckmann, Annalen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loges, Sonja |d 1973- |e VerfasserIn |0 (DE-588)129285463 |0 (DE-627)480392161 |0 (DE-576)297579002 |4 aut | |
| 700 | 1 | |a Reinacher-Schick, Anke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Westphalen, C. Benedikt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lange, Sebastian |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology research and treatment |d Basel : Karger, 2014 |g 47(2024), 9 vom: Sept., Seite 410-419 |h Online-Ressource |w (DE-627)776629611 |w (DE-600)2749752-5 |w (DE-576)400081660 |x 2296-5262 |7 nnas |a What do German Molecular Tumor Boards recommend in patients with PIK3CA-mutated tumors? Launch and first results from the German Transsectoral Molecular Tumor Board exchange platform Deutschland |
| 773 | 1 | 8 | |g volume:47 |g year:2024 |g number:9 |g month:09 |g pages:410-419 |g extent:9 |a What do German Molecular Tumor Boards recommend in patients with PIK3CA-mutated tumors? Launch and first results from the German Transsectoral Molecular Tumor Board exchange platform Deutschland |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000539217 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241217 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 129285463 |a Loges, Sonja |m 129285463:Loges, Sonja |d 60000 |d 63600 |e 60000PL129285463 |e 63600PL129285463 |k 0/60000/ |k 1/60000/63600/ |p 4 | ||
| 999 | |a KXP-PPN1912772132 |e 4637758203 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"776629611","note":["Gesehen am 15.12.2023"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["37.2014 -"],"language":["eng"],"id":{"zdb":["2749752-5"],"issn":["2296-5262"],"eki":["776629611"]},"part":{"text":"47(2024), 9 vom: Sept., Seite 410-419","year":"2024","pages":"410-419","issue":"9","volume":"47","extent":"9"},"origin":[{"dateIssuedDisp":"2014-","publisher":"Karger","dateIssuedKey":"2014","publisherPlace":"Basel"}],"title":[{"title":"Oncology research and treatment","title_sort":"Oncology research and treatment"}],"disp":"What do German Molecular Tumor Boards recommend in patients with PIK3CA-mutated tumors? Launch and first results from the German Transsectoral Molecular Tumor Board exchange platform DeutschlandOncology research and treatment"}],"recId":"1912772132","physDesc":[{"extent":"9 S."}],"language":["eng"],"note":["Online veröffentlicht: 7. May 2024","Gesehen am 17.12.2024"],"person":[{"given":"Ina","family":"Pretzell","role":"aut","display":"Pretzell, Ina"},{"given":"Alexander","family":"Desuki","display":"Desuki, Alexander","role":"aut"},{"family":"Bleckmann","role":"aut","display":"Bleckmann, Annalen","given":"Annalen"},{"given":"Sonja","family":"Loges","display":"Loges, Sonja","role":"aut"},{"given":"Anke","family":"Reinacher-Schick","role":"aut","display":"Reinacher-Schick, Anke"},{"family":"Westphalen","role":"aut","display":"Westphalen, C. Benedikt","given":"C. Benedikt"},{"given":"Sebastian","family":"Lange","role":"aut","display":"Lange, Sebastian"}],"id":{"doi":["10.1159/000539217"],"eki":["1912772132"]},"origin":[{"dateIssuedDisp":"September 2024","dateIssuedKey":"2024"}],"name":{"displayForm":["Ina Pretzell, Alexander Desuki, Annalen Bleckmann, Sonja Loges, Anke Reinacher-Schick, C. Benedikt Westphalen, Sebastian Lange, on behalf of TEAM-D Participants"]},"title":[{"subtitle":"Launch and first results from the German Transsectoral Molecular Tumor Board exchange platform Deutschland","title_sort":"What do German Molecular Tumor Boards recommend in patients with PIK3CA-mutated tumors?","title":"What do German Molecular Tumor Boards recommend in patients with PIK3CA-mutated tumors?"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a PRETZELLINWHATDOGERM2024 | ||